Zacks Investment Research upgraded shares of Leap Therapeutics (NASDAQ:LPTX) from a hold rating to a buy rating in a report published on Tuesday morning. Zacks Investment Research currently has $7.00 price objective on the stock.
According to Zacks, “Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. “
Shares of Leap Therapeutics (NASDAQ LPTX) traded up $0.06 during midday trading on Tuesday, hitting $6.28. 27,422 shares of the stock were exchanged, compared to its average volume of 51,599. Leap Therapeutics has a fifty-two week low of $4.90 and a fifty-two week high of $10.10.
Leap Therapeutics (NASDAQ:LPTX) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). research analysts forecast that Leap Therapeutics will post -3.63 earnings per share for the current fiscal year.
In other news, COO Augustine Lawlor purchased 1,057,769 shares of the business’s stock in a transaction dated Tuesday, November 14th. The stock was acquired at an average price of $6.09 per share, for a total transaction of $6,441,813.21. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 58.40% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/leap-therapeutics-lptx-upgraded-at-zacks-investment-research-2.html.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.